Metagenomi Therapeutics
MGX
50 hedge funds and large institutions have $140M invested in Metagenomi Therapeutics in 2024 Q1 according to their latest regulatory filings, with 50 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
35.53% more ownership
Funds ownership: 0% → 35.53% (+36%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$20.1M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$20M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$15.4M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$14.6M |
| 5 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$8.94M |
Top Sellers
MGX Hedge Fund Activity: Q1 2024 in Review
50 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Metagenomi Therapeutics (MGX) for Q1 2024, worth a combined $140M.
Buyers outnumbered sellers: 50 funds opened new MGX positions and 0 closed out — a net gain of 50 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $20.1M.
- 50 institutional investors held Metagenomi Therapeutics (MGX) as of Q1 2024, up from 0 in Q4 2023.
- Funds reported $140M of Metagenomi Therapeutics stock for Q1 2024.
- 50 funds opened new Metagenomi Therapeutics positions in Q1 2024 and 0 closed out, a net change of +50 holders.
- The largest Metagenomi Therapeutics buyer in Q1 2024 was RA Capital Management, an estimated $20.1M added.
Based on aggregated 13F filings for Q1 2024.